Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Tiotropium to QVA149 in Symptomatic Mild to Moderate COPD
NCT02566031Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Trough Forced Expiratory Volume in 1 Second at 12 weeks. Started Mar 2013; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02566031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566031.